BEDMINSTER, N.J.--(BUSINESS WIRE)--NPS Pharmaceuticals, Inc. (Nasdaq: NPSP) today reported that three abstracts summarizing data from the company’s Phase 3 studies of GATTEX™ (teduglutide) in patients with short bowel syndrome (SBS) were accepted for presentation at the American College of Gastroenterology (ACG) Annual Scientific Meeting and Postgraduate Course in Orlando, Florida, October 3-8, 2008, including an oral presentation of 52-week data from the Phase 3 study of GATTEX™ in SBS patients. The abstract titles and presentation times are summarized below.
